I think it’s definitely something to think about. I think, again, we kind of need more data to parse out the differences between the NHTs in regards to the cardiometabolic risk factors so that we can have more better guidance for patients. Because even when you look at cardiovascular disease or cardiometabolic syndrome, there’s the blood pressure part of it, there’s the lipids part of it, there’s the diabetes part of it...
I think it’s definitely something to think about. I think, again, we kind of need more data to parse out the differences between the NHTs in regards to the cardiometabolic risk factors so that we can have more better guidance for patients. Because even when you look at cardiovascular disease or cardiometabolic syndrome, there’s the blood pressure part of it, there’s the lipids part of it, there’s the diabetes part of it. So I can’t assume that every NHT is the same in terms of the risk for all patients. So I would like more granular information, which I think we need to continue to do more research on to identify. I think at the bare minimum, we could say from what we learned here and other limited research that’s been done on the topic is that we should be aware that we need to look out for these things as toxicities of our medications. And I don’t think it’s a bad idea then in someone that’s, you know, higher risk or that we’re just seeing higher glucose levels with, for example, to order an A1C or do a formal recommendation that they follow up with their primary care, for example, in regards to that, just to kind of detect these things earlier. And at our institution, we have a cardio-oncologist we work very closely with, and we do refer patients to him, and we’re working on setting up a more streamlined system for referral to him based on more standardized criteria for highest risk, high-risk patients in particular.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
